Board Recruitment Announcement
Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the [...]
Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the [...]
Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for [...]
I am writing to you as the co-Principal Investigator on CaringVirtually, a virtual care oncology patient study, requesting your support in sharing information about this study with your patient [...]
CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, [...]
CNETS participates in and supports QEII fall publication on Ga68/NETSPOT accessibility in Atlantic Canada. The QEII Times and the Chronicle Herald published a two-page spread on Saturday, October 16, [...]
Les Cancers Endocriniens, published in Le Médecin du Québec, October 2021 Dre. Cynthia Landry is a primary care physician in Châteauguay, Quebec, working as an emergency physician [...]
Our amazing Hamilton/Halton/Niagara NET Support Group Leader, Vannesa Mann, shares her inspirational story! Zoomer | September 10th, 2021 For people with neuroendocrine tumours, early diagnosis and timely [...]
Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]
CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]
As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]